Diagnostic Imaging for Endometrial Cancer
Trial Summary
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications. However, previous hormonal therapy is allowed, and there are no specific instructions about other medications.
What data supports the effectiveness of the treatment Indocyanine Green Solution, IC-Green, Cardio-Green, Fox Green, ICG, Positron Emission Tomography, PET, Positron Emission Tomography, PET/CT, PET Scan for endometrial cancer?
Research shows that PET/CT scans are valuable in evaluating endometrial cancer, especially for detecting recurrent disease and assessing the extent of cancer spread, which helps in planning treatment. This imaging technique is effective in comparison to conventional imaging methods, providing important information for managing endometrial cancer.12345
Is indocyanine green safe for use in diagnostic imaging for endometrial cancer?
How does the treatment for endometrial cancer using indocyanine green differ from other treatments?
What is the purpose of this trial?
This clinical trial studies positron emission tomography (PET)/computed tomography (CT) and lymph node mapping in finding lymph node metastasis in patients with endometrial cancer that is at high risk of spreading. A PET/CT scan is a procedure that combines the pictures from a PET scan and a CT scan, which are taken at the same time from the same machine. The combined scans give more detailed pictures of areas inside the body than either scan gives by itself. Lymph node mapping uses a radioactive dye, called indocyanine green solution, to identify lymph nodes that may contain cancer cells. PET/CT and sentinel lymph node mapping may be better ways than surgery to identify cancer in the lymph nodes.
Research Team
Pamela T. Soliman
Principal Investigator
M.D. Anderson Cancer Center
Eligibility Criteria
This trial is for patients with high-risk endometrial cancer, including specific types like grade 3 endometrioid, serous, and clear cell cancers. Candidates must be suitable for surgery, have no prior treatment for their cancer except hormonal therapy, and show no signs of disease spread in the abdomen on scans. Women of childbearing age need a negative pregnancy test.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Diagnostic
Patients undergo PET/CT prior to surgery to identify lymph node metastasis
Surgical Staging
Patients undergo intraoperative lymph node mapping with indocyanine green solution during full lymphadenectomy
Follow-up
Participants are monitored for post-operative complications and effectiveness of the diagnostic procedures
Treatment Details
Interventions
- Indocyanine Green Solution
- Positron Emission Tomography
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator